Piergiuseppe Nestola Global Vaccine Technology Consultant at Sartorius

What have we learned from the pandemic and how can we address the coming challenges?

There is a promising pipeline of vaccine candidates, but what happens if the frontrunners fail?

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.

As the world grasps the severity of the ongoing pandemic, we must ask how we can accelerate vaccine development safely.

It is well accepted that vaccine development needs to move faster, but how can companies balance compliance and speed?